Charles L Campbell

Summary

Affiliation: University of Kentucky
Country: USA

Publications

  1. ncbi New treatment options for acute coronary syndromes
    Charles L Campbell
    University of Kentucky, Gill Heart Institute, 900 S Limestone St, 326 Charles T Wethington Bldg, Lexington, KY 40536 0200, USA
    Am J Manag Care 12:S435-43. 2006
  2. ncbi Aspirin dose for the prevention of cardiovascular disease: a systematic review
    Charles L Campbell
    Gill Heart Institute, University of Kentucky, Lexington, USA
    JAMA 297:2018-24. 2007
  3. ncbi Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy
    Charles L Campbell
    Gill Heart Institute, University of Kentucky, 326 Charles T Wethington Building, 900 South Limestone, Lexington, KY 40536 0293, USA
    J Thromb Thrombolysis 31:139-45. 2011
  4. ncbi Salivary biomarkers associated with myocardial necrosis: results from an alcohol septal ablation model
    Joseph D Foley
    Department of Internal Medicine, Division of Cardiovascular Medicine, College of Medicine, University of Kentucky, and the Lexington Veterans Administration Hospital, Lexington, Kentucky
    Oral Surg Oral Med Oral Pathol Oral Radiol 114:616-23. 2012
  5. ncbi G-protein-coupled receptors as signaling targets for antiplatelet therapy
    Susan S Smyth
    Veterans Affairs Medical Center, Department of Medicine, Physiology, and Pharmacology, University of Kentucky, Lexington, KY, USA
    Arterioscler Thromb Vasc Biol 29:449-57. 2009
  6. ncbi Optimal management of hypertension in patients with ischemic heart disease
    Debabrata Mukherjee
    Gill Heart Institute and the Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky 40536 0200, USA
    Cardiovasc Hematol Agents Med Chem 7:198-205. 2009
  7. ncbi Oral antiplatelet therapy for acute coronary syndromes: aspirin, P2Y12 inhibition and thrombin receptor antagonists
    Alison L Bailey
    Gill Heart Institute at University of Kentucky and Lexington Veterans Administration Hospital, Lexington, KY, USA
    Curr Drug Targets 12:1805-12. 2011
  8. ncbi Plasma levels of sphingosine 1-phosphate are strongly correlated with haematocrit, but variably restored by red blood cell transfusions
    Samy Selim
    Division of Cardiovascular Medicine, The Gill Heart Institute, 741 S Limestone Street, Lexington, KY 40536 0509, USA
    Clin Sci (Lond) 121:565-72. 2011
  9. ncbi Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel
    Julie H Oestreich
    Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536 0293, USA
    Coron Artery Dis 20:207-13. 2009
  10. ncbi Oral fluids that detect cardiovascular disease biomarkers
    Joseph D Foley
    Department of Internal Medicine, Division of Cardiovascular Medicine, College of Medicine, University of Kentucky, Lexington, Kentucky 40536 0297, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol 114:207-14. 2012

Collaborators

Detail Information

Publications13

  1. ncbi New treatment options for acute coronary syndromes
    Charles L Campbell
    University of Kentucky, Gill Heart Institute, 900 S Limestone St, 326 Charles T Wethington Bldg, Lexington, KY 40536 0200, USA
    Am J Manag Care 12:S435-43. 2006
    ..This review focuses on novel antithrombotic therapies for ACS, particularly fondaparinux sodium, a synthetic inhibitor of clotting factor Xa...
  2. ncbi Aspirin dose for the prevention of cardiovascular disease: a systematic review
    Charles L Campbell
    Gill Heart Institute, University of Kentucky, Lexington, USA
    JAMA 297:2018-24. 2007
    ..More than 50 million US adults take aspirin regularly for long-term prevention of cardiovascular disease, typically either 81 mg/d or 325 mg/d. Controversy remains regarding the most appropriate long-term daily dose...
  3. ncbi Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy
    Charles L Campbell
    Gill Heart Institute, University of Kentucky, 326 Charles T Wethington Building, 900 South Limestone, Lexington, KY 40536 0293, USA
    J Thromb Thrombolysis 31:139-45. 2011
    ..3.60, P = 0.09). These data suggest that major bleeding is associated with development of a pro-inflammatory state. If confirmed, this mechanism may in part explain the poor prognosis of patients experiencing an acute hemorrhagic event...
  4. ncbi Salivary biomarkers associated with myocardial necrosis: results from an alcohol septal ablation model
    Joseph D Foley
    Department of Internal Medicine, Division of Cardiovascular Medicine, College of Medicine, University of Kentucky, and the Lexington Veterans Administration Hospital, Lexington, Kentucky
    Oral Surg Oral Med Oral Pathol Oral Radiol 114:616-23. 2012
    ..To determine if salivary biomarkers demonstrate utility for identifying aspects of myocardial necrosis...
  5. ncbi G-protein-coupled receptors as signaling targets for antiplatelet therapy
    Susan S Smyth
    Veterans Affairs Medical Center, Department of Medicine, Physiology, and Pharmacology, University of Kentucky, Lexington, KY, USA
    Arterioscler Thromb Vasc Biol 29:449-57. 2009
    ..The identification and development of new agents directed against specific platelet signaling pathways may offer an advantage in preventing thrombotic events while minimizing bleeding risk...
  6. ncbi Optimal management of hypertension in patients with ischemic heart disease
    Debabrata Mukherjee
    Gill Heart Institute and the Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky 40536 0200, USA
    Cardiovasc Hematol Agents Med Chem 7:198-205. 2009
    ....
  7. ncbi Oral antiplatelet therapy for acute coronary syndromes: aspirin, P2Y12 inhibition and thrombin receptor antagonists
    Alison L Bailey
    Gill Heart Institute at University of Kentucky and Lexington Veterans Administration Hospital, Lexington, KY, USA
    Curr Drug Targets 12:1805-12. 2011
    ..This review summarizes ongoing efforts to improve the effectiveness of antiplatelet therapy among patients with ACS...
  8. ncbi Plasma levels of sphingosine 1-phosphate are strongly correlated with haematocrit, but variably restored by red blood cell transfusions
    Samy Selim
    Division of Cardiovascular Medicine, The Gill Heart Institute, 741 S Limestone Street, Lexington, KY 40536 0509, USA
    Clin Sci (Lond) 121:565-72. 2011
    ..Changes in S1P content may contribute to an RBC storage lesion. Further studies should investigate the clinical significance of alterations in circulating S1P levels and the potential value of enriching stored RBCs with S1P...
  9. ncbi Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel
    Julie H Oestreich
    Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536 0293, USA
    Coron Artery Dis 20:207-13. 2009
    ..Studies have shown that the mean aggregation response to clopidogrel can be changed by a higher maintenance dose. However, these studies have not focused on individual changes...
  10. ncbi Oral fluids that detect cardiovascular disease biomarkers
    Joseph D Foley
    Department of Internal Medicine, Division of Cardiovascular Medicine, College of Medicine, University of Kentucky, Lexington, Kentucky 40536 0297, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol 114:207-14. 2012
    ..The aim of this study was to determine the utility of oral fluids for assessment of coronary and cardiovascular (CV) health...
  11. ncbi Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease
    Fredric J Pashkow
    John A Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA
    Am J Cardiol 101:58D-68D. 2008
    ....
  12. ncbi Unraveling questions surrounding clopidogrel resistance and stent thrombosis: one less snag
    David J Moliterno
    J Am Coll Cardiol 49:2318-9. 2007
  13. ncbi Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study
    Charles L Campbell
    Department of Cardiology, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, TX, USA
    Am Heart J 150:796-9. 2005
    ..N-Acetylcysteine (NAC) is able to reduce disulfide bonds. We postulated that NAC might reverse clopidogrel's effect on platelets...